Voyager Therapeutics (NASDAQ:VYGR) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Thursday.

VYGR has been the subject of a number of other reports. BTIG Research reiterated a “buy” rating and set a $32.00 price objective on shares of Voyager Therapeutics in a research note on Monday, September 10th. Morgan Stanley reiterated an “equal weight” rating and set a $27.00 price objective on shares of Voyager Therapeutics in a research note on Monday, September 10th. Chardan Capital reiterated a “hold” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, June 21st. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 11th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $31.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, July 17th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $30.70.

Shares of NASDAQ:VYGR opened at $15.36 on Thursday. The company has a market cap of $519.30 million, a P/E ratio of -5.77 and a beta of 2.94. Voyager Therapeutics has a 12-month low of $11.54 and a 12-month high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.13). The company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $3.00 million. Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%. On average, research analysts predict that Voyager Therapeutics will post -3.12 earnings per share for the current year.

In other Voyager Therapeutics news, Director James A. Geraghty purchased 3,000 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were bought at an average cost of $19.39 per share, with a total value of $58,170.00. Following the acquisition, the director now owns 76,588 shares in the company, valued at $1,485,041.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Glenn Pierce purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was acquired at an average cost of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 11,000 shares of company stock worth $205,300. 33.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Metropolitan Life Insurance Co. NY lifted its holdings in Voyager Therapeutics by 53.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock worth $177,000 after purchasing an additional 3,157 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in Voyager Therapeutics by 38.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock worth $208,000 after purchasing an additional 2,964 shares in the last quarter. Thompson Davis & CO. Inc. lifted its holdings in Voyager Therapeutics by 187.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 11,951 shares of the company’s stock worth $234,000 after purchasing an additional 7,800 shares in the last quarter. Hershey Trust Co. purchased a new position in Voyager Therapeutics in the 2nd quarter worth approximately $284,000. Finally, Commonwealth Equity Services LLC lifted its holdings in Voyager Therapeutics by 27.4% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,272 shares of the company’s stock worth $318,000 after purchasing an additional 3,500 shares in the last quarter. 89.64% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

See Also: Dividend Stocks – Are They Right For You?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.